Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Yakob Liawatidewi Sells 28,816 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Free Report) EVP Yakob Liawatidewi sold 28,816 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $53.13, for a total transaction of $1,530,994.08. Following the completion of the sale, the executive vice president now directly owns 69,669 shares in the company, valued at $3,701,513.97. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Amphastar Pharmaceuticals Stock Up 1.3 %

AMPH stock opened at $53.63 on Wednesday. The company has a 50 day moving average price of $57.63 and a two-hundred day moving average price of $46.11. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.11 and a current ratio of 1.53. The stock has a market capitalization of $2.59 billion, a P/E ratio of 27.50 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a one year low of $26.76 and a one year high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Free Report) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.52 by $0.06. The firm had revenue of $145.71 million during the quarter, compared to analyst estimates of $137.20 million. Amphastar Pharmaceuticals had a net margin of 18.85% and a return on equity of 20.12%. As a group, sell-side analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on AMPH. Jefferies Financial Group started coverage on Amphastar Pharmaceuticals in a research report on Tuesday, July 25th. They set a “buy” rating and a $70.00 price objective for the company. raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 24th. Finally, Piper Sandler boosted their target price on shares of Amphastar Pharmaceuticals from $66.00 to $71.00 in a research note on Wednesday, August 9th.

Read Our Latest Research Report on Amphastar Pharmaceuticals

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in AMPH. West Tower Group LLC acquired a new stake in Amphastar Pharmaceuticals during the second quarter worth about $39,000. Point72 Middle East FZE purchased a new position in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $50,000. Pacer Advisors Inc. acquired a new position in Amphastar Pharmaceuticals during the second quarter valued at approximately $59,000. Point72 Hong Kong Ltd purchased a new stake in Amphastar Pharmaceuticals during the first quarter worth approximately $74,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Amphastar Pharmaceuticals by 206.9% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,998 shares of the company’s stock valued at $75,000 after acquiring an additional 1,347 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).

Recommended Stories

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with's FREE daily email newsletter.